Table 1.

Edoxaban summary

Route of administration	Oral
Onset of action	Rapid
Bioavailability	62%
Development name	DU-176b
IUPAC name	N-(5-chloropyridin-2-yl)-N′-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)-cyclohexyl]ethanediamide p-toluenesulfonate monohydrate
Major indications	NVAF, VTE, major orthopedic surgery (only in Japan)
Pharmacology description	Factor Xa inhibitor
Approval route	Approved in the USA, Europe, and Japan

Abbreviations: IUPAC, International Union of Pure and Applied Chemistry; NVAF, nonvalvular atrial fibrillation; VTE, venous thromboembolism.